Eli Lilly and Co. spent $1.9 million lobbying the federal government in the first quarter, focusing on the health care overhaul and overseas pricing reform, among many other issues.

The maker of the antipsychotic Zyprexa and the antidepressant Cymbalta lobbied on the health care overhaul, the massive law that will eventually provide insurance coverage to millions of Americans. The law also imposes fees on the pharmaceutical industry.

Lilly also covered Medicare prescription drug rebate issues, hospital discounts, pricing reforms in Germany and Greece, and market access in Poland in the April-to-June period. The drugmaker, which is expanding its animal health business, also lobbied on food safety, veterinary medicine and antibiotic issues.

Besides Congress and the White House, Lilly also lobbied the Office of Management and Budget, the U.S. Trade Representative and the departments of State, Treasury, Agriculture, Commerce and Homeland Security.

Lobbyists are required to disclose activities that could influence members of the executive and legislative branches of government under a federal law enacted in 1995.